ASCO 2020：11项中华人民共和国研究入选口头报告，17项Poster报告

受全球取而代之冠传染病受到影响，原订于5月29日~6月2日在芝加哥举行的美国临床学会（ASCO）年会今年将首次以新线上形式举办，这是迄今最大规模的新线上盛会。今天，小组会议的概要题目公布，共103个sessions，当欧美共有11项研究课题崭露头角口头报告，17项崭露头角Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

酮类替尼或希亚替尼加卡培他平野应用于HER2+丙型肝炎乳腺恶病态肿瘤（PHOEBE）：一项III期随机试验病态。

第二场：丙型肝炎乳腺恶病态肿瘤

原作者：当欧美医学科学院所医院徐兵河大学教授、马飞大学教授，复旦大学附属所医院胡夕春大学教授等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态乳腺恶病态肿瘤国际标准病患后卡培他平野维持节拍中风的III期试验病态（SYSUCC-001）。

第二场：乳腺恶病态肿瘤—局部/周围/特别设计病患

原作者：当中山大学卫生保健当其中心王树森大学教授等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用丙型肝炎脑的表型特征来得出结论脑脊液当中循环DNA探测的概率: 取而代之物件对抗据闻关键时刻

第二场：取而代之物件应付据闻问题

原作者：李美芹 李科克等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

了了非尼对比索拉非尼作为中晚期肾细胞会恶病态肿瘤的预备队病患：一项开放页面、随机、多当其中心II/III期试验病态。

第二场：胃部肠道恶病态肿瘤—胃部腹腔、胰腺和自是

原作者：四川大学华西所医院毕锋大学教授、当欧美老百姓解放军双十所医院秦叔逵大学教授等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

当欧美中晚期肾恶病态肿瘤病症阿帕替尼二新线病患：一项随机、安慰剂比对、双盲III期研究课题

第二场：胃部肠道恶病态肿瘤—胃部腹腔、胰腺和自是

原作者：当欧美老百姓解放军双十所医院秦叔逵大学教授、四川大学华西所医院李秋大学教授等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中晚期中风病态卵巢恶病态肿瘤二次细胞会减灭术的一项随机III期试验病态：SOC1 / SGOG-OV2。

栏目：妇产科恶病态肿瘤症

原作者：复旦大学附属当中山所医院臧荣余大学教授等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶病态肿瘤根治病态子宫切除后特别设计病患当中的序贯放中风对比基本上皮肤癌或同步放中风（STARS研究课题）：一项随机、比对、开放页面的III期试验病态。

小组会议：妇产科恶病态肿瘤症

原作者：当中山大学卫生保健当其中心大白大学教授、刘继红大学教授等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：特别设计吉非替尼对比中风应用于可切除的EGFR变异的N1-N2期NSCLC-随机III期临床试验病态的之后总体共存比对。

栏目：肺恶病态肿瘤—非小细胞会局部-周围/小细胞会/其他脸部

原作者：广东省老百姓所医院吴一龙大学教授等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异计移到非小细胞会肺恶病态肿瘤病症预备队酪氨酸酪氨酸类固醇倡议或不倡议积极最前新线局部皮肤癌：III期开放页面临床随机试验病态（SINDAS）的当中期结果（NCT02893332）。

栏目：肺恶病态肿瘤-非小细胞会移到

原作者：四川省老百姓所医院曾铭大学教授等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态被害-1（PD-1）的人源化IgG4单克隆抗体倡议阿昔替尼应用于丙型肝炎黏膜胃部恶病态肿瘤病症的Ib期研究课题的总共存期和生物；也比对。

栏目：胃部恶病态肿瘤/皮肤恶病态肿瘤

原作者：北京大学所医院郭军、盛锡楠大学教授等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠度和结果：CECAR-T细胞会首次人体内试验病态病患中风/难治病态T细胞会急病态抗原脑癌（r/r T-ALL）的可靠度和。小组会议：整合当中的病患关键技术-免疫病患。原作者：王林欣等概要：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中晚期腹腔上皮细胞细胞会恶病态肿瘤病症当中的广泛应用：一项随机的开放页面II期试验病态（ORIENT-2）。小组会议：胃部肠道恶病态肿瘤-胃部腹腔恶病态肿瘤、胰腺恶病态肿瘤和自是道恶病态肿瘤原作者：徐建明大学教授等概要：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T细胞会对质母细胞会瘤的根除病态病患小组会议：当中枢神经系统原作者：代红久、孙斌、杨东、徐晖、朱结缘、魏佳、赵旭东概要：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中晚期错配修复缺陷病症当中的广泛应用小组会议：整合当中的病患学-免疫病患原作者：沈琳大学教授等概要：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 继发病态CD7-CART病患中风/难治病态ACUTE抗原脑癌/淋巴瘤的尚未有人体内临床试验病态小组会议: 整合病态病患学-免疫病患原作者简介：张明志，杨林等概要：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议广泛应用中晚期实体瘤病症的Ib期研究课题小组会议：发展病态病患学--底物凋亡药品和生物学原作者：龚继芳，沈琳大学教授等概要：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议制剂和nedaplatin病患中风病态或丙型肝炎腹腔上皮细胞细胞会恶病态肿瘤（ESCC）病症的II期研究课题。小组会议：胃部肠道恶病态肿瘤-胃部腹腔、胰腺和自是道恶病态肿瘤的研究课题原作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼概要：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.小组会议：胃部肠道恶病态肿瘤-胃部腹腔恶病态肿瘤、胰腺恶病态肿瘤和自是管恶病态肿瘤的二新线病患原作者：宋艳等概要：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA分类器应用于初始活检时探测高等级恶病态肿瘤的尿液外体环状RNA分类器：一项多当其中心的回顾病态研究课题小组会议：泌尿系统生殖系统恶病态肿瘤症---恶病态肿瘤、睾丸恶病态肿瘤和恶病态肿瘤原作者简介：Liaoyuan Li等概要：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部中晚期宫颈恶病态肿瘤并发中风后的特别设计中风小组会议: 妇产科恶病态肿瘤症原作者简介： 李珉珉等概要：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病患甲状腺质病态恶病态肿瘤的相关病态：基于ALTER01031试验病态的比对。会话：鳞状原作者：天津市所医院擅长于大学教授概要：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和年龄对安洛替尼病患后病症结局的受到影响: ALTER01031的亚组比对小组会议：鳞状原作者：天津市所医院擅长于大学教授概要：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对得出结论I-IIIA期非小细胞会肺恶病态肿瘤（NSCLC）病症术后中风: GASTO1035和GASTO1018的结果小组会议：肺恶病态肿瘤-非小细胞会局部-周围病态/小细胞会/小细胞会/其他胸科恶病态肿瘤症原作者：Si-Yu Wang等概要：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会肺恶病态肿瘤（NSCLC）当中EGFR酪氨酸酪氨酸类固醇的取而代之型耐药机制小组会议:肺恶病态肿瘤-非小细胞会丙型肝炎肺恶病态肿瘤原作者简介：赵昕，金玲玲，满宇，欧春花，金兰，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧春花、金兰、薛武、杨绍、范敏概要：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验病态当中中晚期胃部恶病态肿瘤总共存的替代终点小组会议：胃部恶病态肿瘤/皮肤恶病态肿瘤原作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟概要：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病患中风或丙型肝炎原发病态恶病态骨病症的II期研究课题小组会议： 病变原作者：唐丽娜，牛晓辉，姚依林，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王琼、蔡启庆、涂崇奇、范正福、杨瑶概要：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 进一步高度评价安罗替尼在中晚期病变病症多新线病患当中的可靠度和。小组会议：病变原作者：姚伟涛，黄家强，浙江余姚人，王林，杜取而代之辉，田志浩，牛晓颖 姚伟涛、黄家强、浙江余姚人、王鑫、杜鑫辉、田志超、牛晓英概要：11526宣传品：414